Interestingly, a recent study revealed that administration of tofogliflozin decreased both serum ACTH and cortisol levels in patients with T2DM, indicating that tofogliflozin influences the hypothalamic–pituitary–adrenal pathway in this population [35]. The gene discussed is POMC; the disease is type 2 diabetes mellitus.